Deutsche Bank AG reaffirmed their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Tuesday. The firm currently has a GBX 6,200 ($76.73) price target on the biopharmaceutical company’s stock.
AZN has been the topic of several other research reports. Societe Generale reaffirmed a buy rating and set a GBX 7,000 ($86.63) price target on shares of AstraZeneca plc in a research report on Wednesday, September 14th. Morgan Stanley increased their price target on shares of AstraZeneca plc from GBX 5,000 ($61.88) to GBX 5,800 ($71.78) and gave the stock an overweight rating in a research report on Friday, August 19th. Goldman Sachs Group Inc. set a GBX 4,000 ($49.50) price target on shares of AstraZeneca plc and gave the stock a sell rating in a research report on Tuesday, September 6th. Jefferies Group reaffirmed a buy rating and set a GBX 5,800 ($71.78) price target on shares of AstraZeneca plc in a research report on Wednesday, September 21st. Finally, JPMorgan Chase & Co. reaffirmed a neutral rating and set a GBX 4,900 ($60.64) price target on shares of AstraZeneca plc in a research report on Tuesday, August 23rd. Five analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of GBX 4,952.72 ($61.30).
Shares of AstraZeneca plc (LON:AZN) traded down 1.16% on Tuesday, reaching GBX 4992.50. The company had a trading volume of 1,089,573 shares. The firm has a 50-day moving average price of GBX 5,004.92 and a 200 day moving average price of GBX 4,463.08. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The firm’s market capitalization is GBX 63.16 billion.
The business also recently announced a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were given a GBX 68.70 ($0.85) dividend. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.